Biology and genetics of malignant brain tumours

Current Opinion in Neurology

Volumn 11, Issue 6, 1998, Pages 619-625

  Darling, John L ^a   Warr, Tracy J ^a  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH FACTOR; NITROSOUREA; TELOMERASE;

ASTROCYTOMA; BRAIN TUMOR; CELL CYCLE; CHROMOSOME 10; DNA REPAIR; DRUG RESISTANCE; EPENDYMOMA; GENE MAPPING; GENE MUTATION; HUMAN; MEDULLOBLASTOMA; MOLECULAR GENETICS; OLIGODENDROGLIOMA; REVIEW;

ADULT; ASTROCYTOMA; BRAIN NEOPLASMS; CELL TRANSFORMATION, NEOPLASTIC; CEREBELLAR NEOPLASMS; CHILD; DNA MUTATIONAL ANALYSIS; EPENDYMOMA; HUMANS; MEDULLOBLASTOMA; OLIGODENDROGLIOMA; P-GLYCOPROTEIN; PROGNOSIS;

EID: 0031743778     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-199812000-00002     Document Type: Review

References (82)

1. Louis DN. A molecular genetic model of astrocytoma histopathology. Brain Pathol 1997;7:755-764.
2. Hayashi Y, Ueki K, Waha A, Wiestler OD, Louis DN, von Deimling A. Association of EGFR gene amplification and CDKN2 (p16/MTS1) gene deletion in glioblastoma multiforme. Brain Pathol 1997; 7:871-875.
3. Biernat W, Tohma Y, Yonekawa Y, Kleihues P, Ohgaki H. Alterations of cell cycle regulatory genes in primary (de novo) and secondary glioblastomas. Acta Neuropathol (Bert) 1997; 94:303-309.
4. Sure U, Ruedi D, Tachibana O, Yonekawa Y, Ohgaki H, Kleihues P, Hegi ME. Determination of p53 mutations, EGFR overexpression, and loss of p16 expression in pediatric glioblastomas. J Neuropathol Exp Neurol 1997; 56:782-789.
5. Peraud A, Watanabe K, Plate KH, Yonekawa Y, Kleihues P, Ohgaki H. p53 mutations versus EGF receptor expression in giant cell glioblastomas. J Neuropathol Exp Neurol 1997; 56:1236-1241.
6. Meyer-Puttlitz B, Hayashi Y, Waha A, Rollbrocker B, Bostrom J, Wiestler OD, et al. Molecular genetic analysis of giant cell glioblastomas. Am J Pathol 1997; 151:853-857.
7. Maintz D, Fiedler K, Koopmann J, Rollbrocker B, Nechev S, Lenartz D, et al. Molecular genetic evidence for subtypes of oligoastrocytomas. J Neuropathol Exp Neural 1997; 56:1098-1104.
8. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer [see comments]. Science 1997; 275:1943-1947.
9. Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon A, et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 1997; 15:356-362.
10. Bostrom J, Cobbers JM, Wolter M, Tabatabai G, Weber RG, Lichter P, et al. Mutation of the PTEN (MMAC1) tumor suppressor gene in a subset of glioblastomas but not in meningiomas with loss of chromosome arm 10q. Cancer Res 1998; 58:29-33.
11. Chiariello E, Roz L, Albarosa R, Magnani I, Finocchiaro G. PTEN/MMAC1 mutations in primary glioblastomas and short-term cultures of malignant gliomas. Oncogene 1998; 16:541-545.
12. Duerr EM, Rollbrocker B, Hayashi Y, Peters N, Meyer-Puttlitz B, Louis DN, et al. PTEN mutations in gliomas and glioneuronal tumors. Oncogene 1998; 16:2259-2264.
13. Fults D, Pedone CA, Thompson GE, Uchiyama CM, Gumpper KL, Iliev D, et al. Microsatellite deletion mapping on chromosome 10q and mutation analysis of MMAC1, FAS, and MXI1 in human glioblastoma multiforme. Int J Oncol 1998; 12:905-910.
14. Rasheed BK, Stenzel TT, McLendon RE, Parsons R, Friedman AH, Friedman HS, et al. PTEN gene mutations are seen in high-grade but not in low-grade gliomas. Cancer Res 1997; 57:4187-4190.
15. Tohma Y, Gratas C, Biernat W, Peraud A, Fukuda M, Yonekawa Y, et al. PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas. J Neuropathol Exp Neurol 1998; 57:684-689.
16. Wang SI, Pue J, Li J, Bruce JN, Carins P, Sidransky D, Parsons R. Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res 1997; 57:4183-4186.
17. Liu W, James CD, Frederick L, Alderete BE, Jenkins RB. PTEN/MMAC1 mutations and EGFR amplification in glioblastomas. Cancer Res 1997; 57:5254-5257.
18. Ichimura K, Schmidt EE, Miyakawa A, Goike HM, Collins VP. Distinct patterns of deletion on 10p and 10q suggest involvement of multiple tumor suppressor genes in the development of astrocytic gliomas of different malignancy grades. Genes Chromosomes Cancer 1998; 22:9-15.
19. Maier D, Zhang Z, Taylor E, Hamou MF, Gratzi O, Van Meir EG, et al. Somatic deletion mapping on chromosome 10 and sequence analysis of PTEN/MMAC1 point to the 10q25-26 region as the primary target in low-grade and high-grade gliomas. Oncogene 1998; 16(25):3331-3335. This group provides evidence for a novel tumour supresser gene distal to MMAC1/PTEN on 10q.
20. Mollenhauer J, Wiemann S, Scheurlen W, Korn B, Hayashi Y, Wilgenbus KK, et al. DMBT1, a new member of the SRCR superfamily, on chromosome 10q25.3-26.1 is deleted in malignant brain tumours. Nat Genet 1997; 17:32-39. The authors have identified a candidate tumour supresser gene on 10q25.
21. Nakamura H, Yoshida M, Tsuiki H, Ito K, Ueno M, Nakao M, et al. Identification of a human homolog of the Drosophila neuralized gene within the 10q25.1 malignant astrocytoma deletion region. Oncogene 1998; 16:1009-19. The authors have identified a candidate tumour supresser gene on 10q25.
22. Wechsler DS, Shelly CA, Petroff CA, Dang CV. MX11, a putative tumor suppressor gene, suppresses growth of human glioblastoma cells. Cancer Res 1997; 57:4905-4912.
23. Maier D, Comparone D, Taylor E, Zhang Z, Gratzi O, Van Meir EG, et al. New deletion in low-grade oligodendroglioma at the glioblastoma suppressor locus on chromosome 10q25-26. Oncogene 1997; 15:997-1000.
24. Kon H, Sonoda Y, Kumabe T, Yoshimoto T, Sekiya T, Murakami Y. Structural and functional evidence for the presence of tumor suppressor genes on the short arm of chromosome 10 in human gliomas. Oncogene 1998; 16:257-63. This group provides interesting data regarding putative supresser genes on 10p.
25. Voesten AM, Bijleveld EH, Westerveld A, Hulsebos TJ. Fine mapping of a region of common deletion on chromosome arm 10p in human glioma. Genes Chromosomes Cancer 1997; 20:167-172.
26. Almeida A, Zhu XX, Vogt N, Tyagi R, Muleris M, Dutrillaux AM, et al. GAC1, a new member of the leucine-rich repeat superfamily on chromosome band 1q32.1, is amplified and overexpressed in malignant gliomas. Oncogene 1998; 16:2997-3002.
27. Sehgal A, Keener C, Boynton AL, Young RF, Vermeulen SS, Yonemura KS, Kohler EP, et al. Isolation and characterization of a novel gene from human glioblastoma multiforme tumor tissue. Int J Cancer 1997; 71:565-572.
28. Mueller HW, Michel A, Heckel D, Fischer U, Tonnes M, Tsui LC, et al. Identification of an amplified gene cluster in glioma including two novel amplified genes isolated by exon trapping. Hum Genet 1997; 101:190-197.
29. Fischer U, Heckel D, Michel A, Janka M, Hulsebos T, Meese E. Cloning of a novel transcription factor-like gene amplified in human glioma including astrocytoma grade I. Hum Mol Genet 1997; 6:1817-1822.
30. Saitoh Y, Bruner JM, Levin VA, Kyritsis AP. Identification of allelic loss on chromosome arm 6p in human astrocytomas by arbitrarily primed polymerase chain reaction. Genes Chromosomes Cancer 1998; 22:165-170.
31. Wang XY, Smith DI, Frederick L, James CD. Analysis of EGF receptor amplicons reveals amplification of multiple expressed sequences. Oncogene 1998; 16:191-195.
32. Fenstermaker RA, Ciesielski MJ, Castiglia GJ. Tandem duplication of the epidermal growth factor receptor tyrosine kinase and calcium internalization domains in A-172 glioma cells. Oncogene 1998; 16:3435-3443.
33. Zattara-Cannoni H, Gambarelli D, Lena G, Dufour H, Choux M, Grisoli F, Vagner-Capodano AM. Are juvenile pilocytic astrocytomas benign tumors? A cytogenetic study in 24 cases. Cancer Genet Cytogenet 1998; 104:157-160.
34. Zhu JJ, Santarius T, Wu X, Tsong J, Guha A, Wu JK, et al. Screening for loss of heterozygosity and microsatellite instability in oligodendrogliomas. Genes Chromosomes Cancer 1998; 21:207-216.
35. Hamilton RL, Pollack IF. The molecular biology of ependymomas. Brain Pathol 1997; 7:807-822. An interesting review on the genetics of ependymoma.
36. Biegel JA. Genetics of pediatric central nervous system tumors. J Pediatr Hematol Oncol 1997; 19:492-501.
37. Kramer DL, Parmiter AH, Rorke LB, Sutton LN, Biegel JA. Molecular cytogenetic studies of pediatric ependymomas. J Neurooncol 1998; 37:25-33.
38. Rorke LB, Trojanowski JQ, Lee VM, Zimmerman RA, Sutton LN, Biegel JA, et al. Primitive neuroectodermal tumors of the central nervous system. Brain Pathol 1997; 7:765-84. A comprehensive review of the biology and genetics of medulloblastoma.
39. Burnett ME, White EC, Sih S, von Haken MS, Cogen PH. Chromosome arm 17p deletion analysis reveals molecular genetic heterogeneity in supratentorial and infratentorial primitive neuroectodermal tumors of the central nervous system. Cancer Genet Cytogenet 1997; 97:25-31.
40. Orellana C, Hernandez-Marti M, Martinez F, et al. Pediatric brain tumors: loss of heterozygosity at 17p and TP53 gene mutations. Cancer Genet Cytogenet 1998; 102:93-99.
41. Pietsch T, Koch A, Wiestler OD. Molecular genetic studies in medulloblastomas: evidence tor tumor suppressor genes at the chromosomal regions 1q31-32 and 17p13. Klin Padiatr 1997; 209:150-155.
42. Steichen-Gersdorf E, Gassner I, Unsinn K, Sperl W. Persistent hyperplastic primary vitreous in a family with osteoporosis-pseudoglioma syndrome. Clin Dysmorphol 1997; 6:171-176.
43. Slavc I, Rodriguez IR, Mazuruk K, Chader GJ, Biegel JA. Mutation analysis and loss of heterozygosity of PEDF in central nervous system primitive neuroectodermal tumors. Int J Cancer 1997; 72:277-282.
44. Steichen-Gersdort E, Baumgartner M, Kreczy A, Maier H, Fink FM. Deletion mapping on chromosome 17p in medulloblastoma. Br J Cancer 1997; 76:1284-1287.
45. Reardon DA, Michalkiewicz E, Boyett JM, Sublett JE, Entrekin R, Ragsdale ST, et al. Extensive genomic abnormalities in childhood medulloblastoma by comparative genomic hybridization. Cancer Res 1997; 57:4042-4047.
46. Scheurlen WG, Schwabe GC, Joos S, Mollenhauer J, Sorensen N, Kuhl J. Molecular analysis of childhood primitive neuroectodermal tumors defines markers associated with poor outcome. J Clin Oncol 1998; 16:2478-2485.
47. Di Rocco F, Carroll RS, Zhang J, Black PM. Platelet-derived growth factor and its receptor expression in human oligodendrogliomas. Neurosurgery 1998; 42:341-346.
48. Smits A, Funa K. Platelet-derived growth factor (PDGF) in primary brain tumours of neuroglial origin. Histol Histopathol 1998; 13:511-520.
49. Lamszus K, Schmidt NO, Jin L, Laterra J, Zagzag D, Way D, et al. Scatter factor promotes motility of human glioma and neuromicrovascular endothelial cells. Int J Cancer 1998; 75:19-28.
50. Nabeshima K, Shimao Y, Sato S, Kataoka H, Moriyama T, Kawano H, et al. Expression of c-Met correlates with grade of malignancy in human astrocytic tumours: an immunohistochemical study. Histopathology 1997; 31:436-43.
51. Koochekpour S, Jeffers M, Rulong S, Taylor G, Klineberg E, Hudson EA, et al. Met and hepatocyte growth factor/scatter factor expression in human gliomas. Cancer Res 1997; 57:5391-5398.
52. Hirose Y, Kojima M, Sagoh M, Murakami H, Yoshida K, Shimazaki K, Kawase T. Immunohistochemical examination of c-Met protein expression in astrocytic tumors. Acta Neuropathol (Berl) 1998; 95:345-351.
53. Wikstrand CJ, Reist CJ, Archer GE, Zalutsky MR, Bigner DD. The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target. J Neurovirol 1998; 4:148-158.
54. Nagane M, Levitzki A, Gazit A, Cavenee WK, Huang HJ. Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bel-XL and caspase-3-like proteases. Proc Natl Acad Sci U S A 1998; 95:5724-5729. The first report of a role for a truncated form of the EGFR receptor not only in the development of biological aggresiveness, but also drug resistance in malignant glioma.
55. Canute GW, Longo SL, Longo JA, Shetler MM, Coyle TE, Winfield JA, Hahn PJ. The hydroxyurea-induced loss of double-minute chromosomes containing amplified epidermal growth factor receptor genes reduces the tumorigenicity and growth of human glioblastoma multiforme. Neurosurgery 1998; 42:609-616.
56. Le S, Zhu JJ, Anthony DC, Greider CW, Black PM. Telomerase activity in human gliomas. Neurosurgery 1998; 42:1120-1124; discussion 1124-1125.
57. Hiraga S, Ohnishi T, Izumoto S, Miyahara E, Kanemura Y, Matsumura H, Arita N. Telomerase activity and alterations in telomere length in human brain tumors. Cancer Res 1998; 58:2117-2125. The authors report differential expression of telomerase in primary and secondary GBM and suggest a possible role for this enzyme in cell immortalisation in vitro.
58. Sano T, Asai A, Mishima K, Fujimaki T, Kirino T. Telomerase activity in 144 brain tumours. Br J Cancer 1998; 77:1633-1637.
59. Kleinschmidt-DeMasters BK, Hashizumi TL, Sze CI, Lillehei KO, Shroyer AL, Shroyer KR. Telomerase expression shows differences across multiple regions of oligodendroglioma versus high grade astrocytomas but shows correlation with Mib-1 labelling. J Clin Pathol 1998; 51:284-293.
60. Kondo S, Tanaka Y, Kondo Y, Hitomi M, Barnett GH, Ishizaka Y, et al. Antisense telomerase treatment: induction of two distinct pathways, apoptosis and differentiation. FASEB J 1998; 12:801-811.
61. Kondo Y, Kondo S, Tanaka Y, Haqqi T, Barna BP, Cowell JK. Inhibition of telomerase increases the susceptibility of human malignant glioblastoma cells to cisplatin-induced apoptosis. Oncogene 1998; 16:2243-2248. Telomerase might be of importance in drug resistance in malignant glioma.
62. Silber JR, Bobola MS, Ghatan S, Blank A, Kolstoe DD, Berger MS. O6-methylguanine-DNA methyltransferase activity in adult gliomas: relation to patient and tumor characteristics. Cancer Res 1998; 58:1068-1073.
63. Beith J, Hartley J, Darling J, Souhami R. DNA interstrand cross-linking and cytotoxicity induced by chloroethylnitrosoureas and cisplatin in human glioma cell lines which vary in cellular concentration of O6-alkylguanine-DNA alkyltransferase. Br J Cancer 1997; 75:500-505.
64. McLendon RE, Cleveland L, Pegram C, Bigner SH, Bigner DD, Friedman HS. Immunohistochemical detection of the DNA repair enzyme O6-methylguanine-DNA methyltransferase in formalin-fixed, paraffin-embedded astrocytomas. Lab Invest 1998; 78:643-644.
65. Maier H, Jones C, Jasani B, Ofner D, Zeiger B, Schmid KW, Budka H. Metallothionein overexpression in human brain tumours. Acta Neuropathol (Berl) 1997; 94:599-604.
66. Becker I, Becker KF, Meyermann R, Hollt V. The multidrug-resistance gene MDR1 is expressed in human glial tumors. Acta Neuropathol 1991; 82:516-519.
67. Matsumoto T, Tani E, Kaba K, Shindo H, Miyaji K. Expression of P-glycoprotein in human glioma cell lines and surgical glioma specimens. J Neurosurg 1991; 74:460-6.
68. Chou PM, Barquin N, Gonzalez-Crussi F, Ridaura Sanz C, Tomita T, Reyes-Mugica M. Ependymomas in children express the multidrug resistance gene: immunohistochemical and molecular biologic study. Pediatr Pathol Lab Med 1996; 16:551-561.
69. Geddes JF, Vowles GH, Ashmore SM, Cockbum HA, Darling JL. Detection of multidrug resistance gene product (P-glycoprotein) expression in ependymomas. Neuropathol Appl Neurobiol 1994; 20:118-121.
70. Chan HS, Ling V. Anti-P-glycoprotein antibody C219 cross-reactivity with c-erbB2 protein: diagnostic and clinical implications [editorial; comment]. J Natl Cancer Inst 1997; 89:1473-1476.
71. Liu B, Sun D, Xia W, Hung MC, Yu D. Cross-reactivity of C219 anti-p170(mdr-1) antibody with p185(c-erbB2) in breast cancer cells: cautions on evaluating p170(mdr-1). J Natl Cancer Inst 1997; 89:1524-1529.
72. Rao VV, Anthony DC, Piwnica-Worms D. Multidrug resistance P-glycoprotein monoclonal antibody JSB-1 crossreacts with pyruvate carboxylase. J Histochem Cytochem 1995; 43:1187-1192.
73. Iwadate Y, Fujimoto S, Tagawa M, Namba H, Sueyoshi K, Hirose M, Sakiyama S. Association of p53 gene mutation with decreased chemosensitivity in human malignant gliomas. Int J Cancer 1996; 69:236-240.
74. Iwadate Y, Tagawa M, Fujimoto S, Hirose M, Namba H, Sueyoshi K, et al. Mutation of the p53 gene in human astrocytic tumours correlates with increased resistance to DNA-damaging agents but not to anti-microtubule anti-cancer agents. Br J Cancer 1998; 77:547-551.
75. Tada M, Iggo RD, Waridel F, Nozaki M, Matsumoto R, Sawamura Y, et al. Reappraisal of p53 mutations in human malignant astrocytic neoplasms by p53 functional assay: comparison with conventional structural analyses. Mol Carcinog 1997; 18:171-176.
76. Tada M, Matsumoto R, Iggo RD, Onimaru R, Shirato H, Sawamura Y, Shinohe Y. Selective sensitivity to radiation of cerebral glioblastomas harboring p53 mutations. Cancer Res 1998; 58:1793-1797. An interesting paper which suggests that p53 mutation can lead to sensitivity to radiation at least in some subpopulations of patients with GBM.
77. Geng L, Walter S, Melian E, Vaughan AT. Transfection of a vector expressing wild-type p53 into cells of two human glioma cell lines enhances radiation toxicity. Radiat Res 1998; 150:31-37.
78. Fueyo J, Gomez-Manzano C, Puduvalli VK, Marin-Duque P, Perez-Soler R, Levin VA, et al. Adenovirus-mediated p16 transfer to glioma cells induces G1 arrest and protects from paclitaxel and topotecan: implications for therapy. Int J Oncol 1998; 12:665-669.
79. Hama S, Heike Y, Naruse I, Takahashi M, Yoshioka H, Arita K, et al. Adenovirus-mediated p16 gene transfer prevents drug-induced cell death through G1 arrest in human glioma cells. Int J Cancer 1998; 77:47-54.
80. Ruan S, Okcu MF, Ren JP, Chiao P, Andreeff M, Levin V, Zhang W. Overexpressed WAF1/Cip1 renders glioblastoma cells resistant to chemotherapy agents 1,3-bis(2-chloroethyl)-1-nitrosourea and cisplatin. Cancer Res 1998; 58:1538-1543.
81. Friedman HS, Johnson SP, Dong Q, Schold SC, Rasheed BK, Bigner SH, et al. Methylator resistance mediated by mismatch repair deficiency in a glioblastoma multiforme xenograft. Cancer Res 1997; 57:2933-29336. [Published erratum appears in Cancer Res 1997; 57:4973.] The authors suggest that mismatch repair might be important in the development of resistance to drugs such as procarbazine and temozolomide, although the study is based on the use of a xenograft with induced resistance to methylating agents rather than patients' samples.
82. El-Deredy W, Ashmore SM, Branston NM, Darling JL, Williams SR, Thomas DG. Pretreatment prediction of the chemotherapeutic response of human glioma cell cultures using nuclear magnetic resonance spectroscopy and artificial neural networks. Cancer Res 1997; 57:4196-4199. This in-vitro study of the use of a combination of proton magnetic resonance spectroscopy and pattern recognition techniques might be the basis for the development of non-invasive neuroradiological assessment of chemosensitivity in the future.